Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously.
The drug giant $(LLY)$ is also reducing the price of 2.5 mg and 5 mg vials of Zepbound, a treatment for diabetes or obesity, that has become highly popular with patients but has also been criticized for its high cost.
Lilly said it will lower the price of the 2.5 mg dose to $349 a month and cut the price of the 5 mg dose to $499 a month.
The company's new Zepbound Self Pay Journey Program offers the 7.5 mg and 10 mg doses at the new price with refills that come within 45 days of prior delivery.
Lilly's stock was up 0.8% premarket.
-Ciara Linnane
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
February 25, 2025 06:57 ET (11:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.